Scientists Crack the Ancient Origins of THC, CBD, and CBC

Resurrected Enzymes Reveal How Cannabis Became Nature's Pharmacy

For decades, scientists knew that cannabis produces THC, CBD, CBC, and dozens of other cannabinoids through a complex biochemical process. What they did not know — until now — was how the plant acquired the ability to make these compounds in the first place.

Researchers at Wageningen University and Research in the Netherlands have answered that question by doing something remarkable: they resurrected enzymes that were active millions of years ago in the ancestors of modern cannabis plants. By reconstructing these extinct molecular machines, the team traced the evolutionary history of cannabinoid production from a single, versatile ancestral enzyme to the specialized enzymes that produce specific cannabinoids today.

The study, published in Plant Biotechnology Journal in late December 2025 and widely covered in early 2026, does more than satisfy scientific curiosity. The resurrected enzymes turned out to be easier to produce in microorganisms like yeast than their modern counterparts — a finding that could accelerate the biotechnological production of cannabinoids for medical applications and open new frontiers in pharmaceutical development.

The Ancestral Enzyme That Started It All

The story of cannabinoids begins with a single enzyme that existed in an ancient ancestor of the cannabis plant. This ancestral enzyme was not specialized. Unlike the modern enzymes that produce THC, CBD, or CBC individually, the ancient enzyme was a generalist — capable of producing several different cannabinoids simultaneously.

This is a common pattern in evolutionary biology. Enzymes often start as jacks-of-all-trades and, over millions of years of evolution, become specialists through a process driven by gene duplication. When a gene is duplicated, the organism ends up with two copies of the same enzyme. One copy continues performing the original function while the other is free to accumulate mutations. Over time, these mutations can cause the duplicate enzyme to become better at producing one specific compound while losing the ability to make others.

This is precisely what happened with cannabinoid enzymes. The Wageningen team demonstrated that after the ancestral gene was duplicated, separate lineages of enzymes evolved that specialized in producing THCA (the precursor to THC), CBDA (the precursor to CBD), and CBCA (the precursor to CBC). Each of these specialized enzymes became highly efficient at producing its particular cannabinoid, but at the cost of the ancestral versatility.

The research team used a computational technique called ancestral sequence reconstruction to infer what these ancient enzymes looked like. By analyzing the DNA sequences of modern cannabinoid enzymes and using sophisticated algorithms to work backward through evolutionary time, they predicted the amino acid sequences of enzymes that existed at various branch points in the cannabinoid enzyme family tree. They then synthesized these predicted sequences in the laboratory and tested whether the reconstructed enzymes actually worked.

Resurrecting Million-Year-Old Enzymes

The experimental validation was the most remarkable part of the study. The team produced the reconstructed ancestral enzymes in laboratory settings and tested their ability to produce cannabinoids. The results confirmed the computational predictions: the oldest reconstructed enzymes were indeed generalists, producing multiple cannabinoids. As the reconstructed enzymes moved closer to the present day on the evolutionary timeline, they became increasingly specialized.

One particularly noteworthy finding involved an evolutionary intermediate — an enzyme that existed at a midpoint in the divergence between the modern THCA, CBDA, and CBCA synthases. This intermediate enzyme was found to produce CBC with high specificity. CBC, or cannabichromene, is a cannabinoid that has attracted growing research attention for its anti-inflammatory and analgesic properties. Having an enzyme that produces CBC efficiently could be valuable for pharmaceutical development, where obtaining pure cannabinoids in large quantities is a persistent challenge.

The ancestral enzymes also proved to be more robust and easier to produce in microorganisms than their modern descendants. When the researchers expressed the ancient enzymes in yeast cells — a common platform for biotechnological production — they found that the ancestral versions were more stable and produced higher yields than the modern enzymes. This is not unusual in ancestral reconstruction studies; ancient proteins are often more thermostable and more tolerant of different conditions than their modern counterparts, likely because they evolved in organisms that faced more variable environments.

Why This Matters for Medical Cannabis

The implications for medical cannabis are substantial. Currently, most cannabinoids used in medical research and pharmaceutical products come from one of two sources: extraction from cannabis plants or chemical synthesis in the laboratory. Both approaches have significant limitations.

Plant-based extraction is constrained by agricultural variables — growing conditions, plant genetics, harvest timing, and extraction efficiency all affect the purity and consistency of the final product. And because cannabis plants produce dozens of cannabinoids simultaneously, isolating a single compound requires extensive purification that adds cost and complexity.

Chemical synthesis can produce pure cannabinoids but is often expensive and environmentally demanding, involving multiple reaction steps and hazardous solvents. For common cannabinoids like THC and CBD, the economics of synthesis can be prohibitive compared to plant-based extraction.

Biotechnological production — using engineered microorganisms like yeast or bacteria to produce cannabinoids through fermentation — represents a third path that could combine the purity of chemical synthesis with the cost-effectiveness of biological production. This approach has been under development for several years, but a persistent bottleneck has been the difficulty of expressing cannabis enzymes in microbial hosts.

The Wageningen team's discovery that ancestral cannabinoid enzymes are more easily produced in yeast than modern enzymes directly addresses this bottleneck. If the ancestral or intermediate enzymes can be optimized for industrial fermentation, it could make biotechnological cannabinoid production commercially viable at scale for the first time.

The CBC Opportunity

Among the specific findings, the discovery of an ancestral enzyme that efficiently produces CBC is particularly exciting. CBC has been called the "forgotten cannabinoid" because it has received far less research attention than THC or CBD, despite showing promising therapeutic properties in preliminary studies.

Research has shown that CBC has anti-inflammatory effects that work through mechanisms different from those of CBD, suggesting potential as a complementary therapy. It has also demonstrated analgesic properties — the ability to reduce pain — in animal models, without the psychoactive effects associated with THC. Additionally, CBC has shown potential neuroprotective properties and may support the growth of new brain cells.

The challenge with CBC research has always been supply. Cannabis plants produce CBC in much smaller quantities than THC or CBD, making it expensive and difficult to obtain in the pure form needed for clinical trials. An enzyme that produces CBC efficiently and can be expressed in yeast could solve this supply problem, potentially accelerating CBC from a promising curiosity to a clinically validated medicine.

Broader Implications for Cannabinoid Science

The Wageningen study contributes to a broader revolution in our understanding of how cannabis works at the molecular level. In 2026 alone, more than 70 cannabis-related studies have been published, exploring everything from the plant's genetics to the clinical applications of individual cannabinoids.

The enzyme evolution research complements other recent advances, including the identification of novel cannabinoids that were previously unknown, the development of new delivery technologies like nano-emulsions that improve cannabinoid bioavailability, and the growing understanding of how different cannabinoids interact with each other and with the human endocannabinoid system.

Together, these advances are moving cannabis science beyond the simple THC-versus-CBD framework that has dominated public understanding. The cannabis plant produces more than 100 identified cannabinoids, each with a distinct chemical structure and potentially distinct therapeutic properties. Understanding the evolutionary relationships between these compounds and the enzymes that produce them is fundamental to unlocking the full medical potential of the plant.

What This Means for the Future

The practical applications of the Wageningen research will take years to fully materialize. Scaling up enzyme production from laboratory demonstration to industrial fermentation requires significant engineering work. Regulatory approvals for biotechnologically produced cannabinoids will need to be obtained. And clinical trials will be necessary to validate the therapeutic potential of compounds like CBC.

But the foundational science is now in place. We know how cannabinoid enzymes evolved, we can reconstruct and modify ancestral versions of those enzymes, and we have demonstrated that those ancestral enzymes can be produced in microorganisms more easily than their modern counterparts. Each of these findings represents a building block for a future in which the full diversity of cannabis chemistry is accessible for medical research and treatment.

For cannabis consumers and patients, the message is one of cautious optimism. The science of cannabis is advancing rapidly, and the tools being developed by researchers like the Wageningen team have the potential to transform how cannabinoids are produced, studied, and used in medicine. The ancient enzymes that nature abandoned millions of years ago may turn out to be exactly what modern medicine needs.